Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT03342144

Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting

Conditions: Chronic Lymphocytic Leukemia (CLL)

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Enrollment: 500

Sponsor: AbbVie

Location: Universitaetsklinikum St. Poelten /ID# 221152 Sankt Pölten Lower Austria

Summary

An observational study to assess the effectiveness, health economic-relevant costs and participant reported outcomes in participants with Chronic lymphocytic leukemia (CLL) receiving venetoclax as a monotherapy or in combination with rituximab, obinutuzumab, ibrutinib, or acalabrutinib as prescribed at the discretion of the physician and in accordance with local clinical practice and label.

Eligibility Criteria

Inclusion Criteria: \- Participant with chronic lymphocytic leukemia (CLL) who start venetoclax therapy can be included in the study if treated as specified in the local label for any specific line of treatment. Exclusion Criteria: \- None

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT03342144). StuddyBuddy aggregates publicly available trial information.